You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

460 Results
Guidelines and Advice
Status: Current
Apr 2020
Guidelines and Advice
Status: Current
ID: ES 6-25
Oct 2024
Guidelines and Advice
Status: Current
ID: GL END 7-24
Nov 2024
Guidelines and Advice
Status: In-Review
ID: GL END 7-3
Version: 4
Apr 2020
Drug
Other Name(s): Somatuline® Autogel®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2024
Drug
Other Name(s): Imfinzi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
  • Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
PACLitaxel,
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet (AC-PACL(DD)), Patient Info Sheet (AC-PACL(DD)+TRAS)
Jan 2024
Guidelines and Advice
Status: In-Review
ID: 3-22
Version: N/A
Apr 2020
Guidelines and Advice
Status: Current
ID: GL1-10
Version: 4
Mar 2024
Drug
Other Name(s): Zometa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2024
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020
Drug
Other Name(s): Xgeva®; Wyost™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2024

Pages